Sensitive

Response to opioid analgesics in cancer (pain decrease)

ABAT · rs1641025

What each result means

C/C Published research associates this genotype with typical/baseline likelihood of Response to opioid analgesics in cancer (pain decrease) — no copies of the reported risk allele. (GWAS Catalog, Neuropsychopharmacol Rep 2018, PMID:30277654)
C/T Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Response to opioid analgesics in cancer (pain decrease). (GWAS Catalog, Neuropsychopharmacol Rep 2018, PMID:30277654)
T/T Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Response to opioid analgesics in cancer (pain decrease) compared to the general population. (GWAS Catalog, Neuropsychopharmacol Rep 2018, PMID:30277654)

Source: GWAS Catalog, Neuropsychopharmacol Rep 2018, PMID:30277654

Questions about rs1641025

What is rs1641025?

rs1641025 is a single position in the genome, in or near the ABAT gene. Published research associates it with response to opioid analgesics in cancer (pain decrease). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

Does having rs1641025 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs1641025 come from?

GWAS Catalog, Neuropsychopharmacol Rep 2018, PMID:30277654. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

← See all variants